Abigail Brooks, MA

Results from the phase 3 ATLANTIS study showed amitriptyline was superior to placebo across multiple symptom-based outcomes for patients with IBS.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

Results showed autologous FMT was safe and well-tolerated but did not affect time to normalized intestinal habits compared to placebo.

Findings from a systematic review and meta-analysis revealed the pooled incidence rate of cerebrovascular accidents in patients with IBD was greater than in the general population.

Announced by AbbVie on October 15, 2023, positive results revealed 59% of patients treated with risankizumab and 40% of patients treated with ustekinumab achieved clinical remission, respectively.

Use of mirtazapine, nortriptyline, and trazodone among hospitalized patients was associated with a greater risk of CDI.

During the long-term extension of the GALAXI trial, 54.1% of participants treated with guselkumab achieved clinical remission and 34.7% achieved endoscopic response.

Patients with IgA nephropathy experienced nearly 30% proteinuria reduction after 6 months of treatment with SGLT2 inhibitors.

The approval of oral, once-daily etrasimod 2 mg was based on positive data from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials.

Screen time ≥2 hours/day at 8 years of age was associated with an increased risk of developing IBD.

More than half of patients in the mirikizumab arm achieved clinical remission at week 52.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

Age, fecal calprotectin level, toxin B PCR cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent CDI.

Fibrosis regression was prevalent among 57% of the cohort and was associated with older age and advanced fibrosis at baseline.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

Social vulnerability index, race, and poverty were associated with increased rates of CDI, calling attention to population-level health disparities.

Mazen Noureddin, MD, MHSc discusses results from the phase 2a trial of HU6 and explains its significant impact on liver fat and body weight.

Syed Ali Husain, MD, MPH, discusses the importance of kidney transplantation, waitlisting, and how disparities in access to transplantation should be addressed.

Obesity rates in the US have skyrocketed, and so has the prevalence of several comorbid gastrointestinal and hepatic diseases - not all patients know their risks or have the financial means to take preventative measures.

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

Patients aged less than 45 years at NAFLD onset had a higher risk of cancer compared to older age groups, highlighting an association between younger age at NAFLD onset and cancer risk.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

Findings from a meta-analysis are calling attention to the viability of classification and risk stratification using greater albuminuria and decreased eGFR.

Among a cohort of young patients with no major comorbidity burdens, 49% were not waitlisted within 5 years of dialysis initiation.

Results showed a significant improvement in patient-reported physical well-being after 12 weeks of treatment with sofosbuvir/velpatasvir.

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

More than 90% of patients with CDI treated with WMT achieved clinical cure, while only 3.8% of WMTs resulted in adverse events.

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990-2019.